Protara Therapeutics (TARA) Cash from Financing Activities (2014 - 2026)
Protara Therapeutics (TARA) posted quarterly Cash from Financing Activities of $1.1 million for Q1 2026, down 33.87% year-over-year from $1.7 million in Q1 2025, and down 98.59% quarter-over-quarter from $81.0 million in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Cash from Financing Activities for 13 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 33.87% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $82.1 million (down 42.03% YoY), while the FY2025 annual figure was $82.7 million, down 40.86% from the prior year.
- Cash from Financing Activities retreated to $1.1 million in Q1 2026 per TARA's latest filing, from $81.0 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $97.8 million in Q4 2024 and bottomed at -$76000.0 in Q1 2024.
- Historically, Cash from Financing Activities has averaged $18.6 million across 5 years, with a median of $10500.0 in 2025.
- On a YoY basis, Cash from Financing Activities climbed as much as 2376.32% in 2025 and fell as far as 99.98% in 2025.
- Protara Therapeutics' Cash from Financing Activities stood at -$18000.0 in 2022, then slumped by 50.0% to -$27000.0 in 2023, then surged by 362503.7% to $97.8 million in 2024, then dropped by 17.26% to $81.0 million in 2025, then sank by 98.59% to $1.1 million in 2026.
- Business Quant data shows TARA's Cash from Financing Activities at $1.1 million in Q1 2026, $81.0 million in Q4 2025, and $13000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - | -26,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26,000.00 |
| Mar 31, 2026 | 1.14 Mn |
| Dec 31, 2025 | 80.96 Mn |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | 1.73 Mn |
| Dec 31, 2024 | 97.85 Mn |
| Jun 30, 2024 | 42.09 Mn |
| Mar 31, 2024 | -76,000.00 |
| Sep 30, 2023 | -27,000.00 |
| Mar 31, 2023 | -64,000.00 |
| Sep 30, 2022 | -18,000.00 |
| Mar 31, 2022 | -72,000.00 |
| Mar 31, 2021 | -228,000.00 |
| Dec 31, 2020 | 10.72 Mn |
| Sep 30, 2020 | 139.83 Mn |
| Jun 30, 2020 | -371,000.00 |
| Mar 31, 2020 | 39.23 Mn |
| Dec 31, 2019 | 1.00 |
| Dec 31, 2018 | 48,000.00 |